GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ajanta Pharma Ltd (BOM:532331) » Definitions » Capex-to-Operating-Cash-Flow

Ajanta Pharma (BOM:532331) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Ajanta Pharma Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Ajanta Pharma's Capital Expenditure for the three months ended in Mar. 2024 was ₹0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was ₹0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Ajanta Pharma Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Ajanta Pharma's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ajanta Pharma Capex-to-Operating-Cash-Flow Chart

Ajanta Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.30 0.27 0.22 0.19

Ajanta Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ajanta Pharma's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ajanta Pharma's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Ajanta Pharma's Capex-to-Operating-Cash-Flow falls into.



Ajanta Pharma Capex-to-Operating-Cash-Flow Calculation

Ajanta Pharma's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1524.1) / 7850.7
=0.19

Ajanta Pharma's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ajanta Pharma  (BOM:532331) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Ajanta Pharma Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Ajanta Pharma's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Ajanta Pharma (BOM:532331) Business Description

Traded in Other Exchanges
Address
Ajanta House, 98 Government Industrial Area, Charkop, Kandivli (West), Mumbai, MH, IND, 400 067
Ajanta Pharma Ltd is a drug manufacturing company with a focus on specialty pharmaceutical products. The company maintains a global presence while generating the vast majority of its revenue in Africa and India. Ajanta's strategy aims to successfully select molecules and products for development while enhancing its research and development capabilities. The company works to develop formulations in different dosages such as tablets, cream, capsules, liquid, and lotion. The company's manufacturing plants are located in India.

Ajanta Pharma (BOM:532331) Headlines

No Headlines